文献速递肺结节与肺癌

Garsorasib治疗中国KRASG12C突变非小细胞肺癌的2期试验

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2024-06-10

这项开放标签、多中心、单臂2期试验纳入123例经铂类化疗和免疫检查点抑制剂治疗后进展的KRASG12C突变NSCLC患者,口服garsorasib 600mg每日两次。独立评审委员会确认的客观缓解率为50%(95%CI 41-59),95%患者出现治疗相关不良事件,50%为3级及以上,常见为肝酶升高和胃肠道事件。

要点

  • 经治KRASG12C突变NSCLC患者中,garsorasib的IRC确认ORR达50%。
  • 95%患者发生治疗相关不良事件,50%为3级及以上,以肝酶升高和恶心呕吐为主。
  • 安全性总体可控,未发现新的安全信号。

核心结论

  • Garsorasib在经治KRASG12C突变NSCLC患者中显示出高缓解率、较长缓解持续时间及可接受且可管理的安全性。

研究设计与样本

  • 开放标签、多中心、单臂2期试验,在中国43家医院纳入123例既往接受铂类化疗和免疫检查点抑制剂治疗的KRASG12C突变NSCLC成人患者。
  • 患者口服garsorasib 600mg每日两次,主要终点为独立评审委员会按RECIST 1.1评估的客观缓解率。

主要发现

  • IRC确认的ORR为50%(61/123,95%CI 41-59)。
  • 95%(117/123)患者报告治疗相关不良事件,50%(61/123)发生3级及以上事件。

关键数值与推荐

  • 3级及以上不良事件最常见为肝酶升高:AST升高21例(17%)、ALT升高19例(15%)、GGT升高28例(23%)。
  • 恶心2例(2%)、呕吐2例(2%)为3级及以上不良事件。
  • 未发现新的安全信号,大多数不良事件得到良好管理。

临床怎么用

  • 对于既往接受过铂类化疗和免疫检查点抑制剂治疗的KRASG12C突变NSCLC患者,garsorasib可作为潜在治疗选择。
  • 治疗期间需重点监测肝酶和胃肠道不良事件,3级及以上事件发生率为50%。

局限性

  • 单臂设计,无对照组。
  • 仅纳入中国患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Garsorasib (D-1553; InventisBio, Shangai, China), a potent KRASG12C inhibitor, has shown promising antitumour activity in patients with KRASG12C-mutated (ie, Gly12Cys) non-small-cell lung cancer (NSCLC) in a phase 1 study. We report results from a phase 2 study conducted to evaluate the efficacy and safety of garsorasib in patients with locally advanced or metastatic KRASG12C-mutated NSCLC. METHODS: This open-label, multicentre, single-arm, phase 2 trial enrolled adult patients with KRASG12C-mutated NSCLC who had previously been treated with platinum-based chemotherapy and immune checkpoint inhibitors from 43 hospitals in China. Participants received 600 mg garsorasib orally twice per day. Tumour assessments were performed at baseline, at the end of every two cycles (of 21 days) for the first eight cycles, and at the end of every three cycles thereafter. The primary endpoint was objective response rate (ORR) as assessed by an independent review committee (IRC) following the guidelines in Response Evaluation Criteria in Solid Tumours, version 1.1. Efficacy and safety were assessed in all patients who received at least one dose of garsorasib. This trial is registered at ClinicalTrials.gov, NCT05383898, and is active but no longer recruiting. FINDINGS: From June 17, 2022, to May 17, 2023, of 225 patients screened for eligibility, 123 patients were enrolled and treated with garsorasib. Of these 123 participants, the median age was 64 years (IQR 59-68), 108 (88%) were male and 15 (12%) were female. At data cutoff (Nov 17, 2023), the median follow-up duration was 7·9 months (IQR 6·3-10·4), and 82 (67%) of 123 patients had discontinued treatment. The IRC-confirmed ORR was 50% (61 of 123 patients; 95% CI 41-59). 117 (95%) of 123 patients reported treatment-related adverse events, with 61 (50%) experiencing grade 3 or higher events. The most common types of adverse events of grade 3 or higher associated with garsorasib were hepatic and gastrointestinal events, including increased liver enzymes, such as aspartate aminotransferase (21 [17%] of 123 participants), alanine aminotransferase (19 [15%] of 123 participants), and gamma-glutamyltransferase (28 [23%] of 123 participants); nausea (2 [2%] of 123 participants); and vomiting (2 [2%] of 123 participants). No new safety signals were identified, and most of the adverse events were well managed. INTERPRETATION: The results show that garsorasib has a high response rate, long duration of response, and an acceptable and manageable safety profile in patients with previously treated KRASG12C-mutated NSCLC. Garsorasib potentially provides a promising treatment option for this patient population. FUNDING: InventisBio.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Li Z, Dang X, Huang D, et al. Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2024. PMID: 38870979. doi:10.1016/S2213-2600(24)00110-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。